多中心比较22C3 PharmDx(Agilent)与SP263(Ventana)检测PD-L1表达用于接受免疫检查点抑制剂治疗的NSCLC患者
意大利病理学会与肿瘤内科学会在4个中心采用组织芯片连续切片,对100例肺腺癌用22C3与SP263两种PD-L1免疫组化检测进行本地染色和评分。在≥50%和≥1%临床相关阈值下,两种检测总体一致性分别为0.99(95%CI 0.96-1)和0.80(95%CI 0.68-0.91)。作者认为两种检测高度相关,可能可互换用于筛选接受帕博利珠单抗及潜在其他抗PD-1/PD-L1药物治疗的患者。
要点
- 在≥50%阈值下22C3与SP263的总体一致性为0.99(95%CI 0.96-1)。
- 在≥1%阈值下两种检测总体一致性为0.80(95%CI 0.68-0.91)。
- ≥1%阈值下一致性较低主要与每种克隆在该阈值下评分者间一致性较低(约80%)有关。
核心结论
- 作者认为两种检测在NSCLC中获得的PD-L1免疫组化表达数据高度相关,提示两种检测可能可互换用于辅助筛选接受一线和二线帕博利珠单抗及潜在其他抗PD-1/PD-L1检查点抑制剂治疗的患者。
研究设计与样本
- 意大利病理学会与意大利肿瘤内科学会开展了一项独立、多中心研究,在4个中心采用组织芯片连续切片对100例肺腺癌进行本地染色和评分,使用相同抗体批次,比较Dako Autostainer平台上的22C3 pharmDx检测与Ventana BenchMark平台上的SP263检测。
主要发现
- 在较低95%置信区间值处,22C3与SP263获得的PD-L1表达水平之间分析相关性高于90%。
- 在≥50%阈值下,22C3与SP263数据的总体一致性为0.99(95%CI:0.96-1)。
- 在≥1%阈值下,22C3与SP263数据的总体一致性为0.80(95%CI:0.68-0.91)。
- 在≥1%阈值下两种克隆间一致性较低主要与每种克隆在该阈值下评分者间一致性较低(约80%)有关。
关键数值与推荐
- 在≥50%临床相关阈值下,22C3与SP263的总体一致性为0.99(95%CI:0.96-1)。
- 在≥1%临床相关阈值下,22C3与SP263的总体一致性为0.80(95%CI:0.68-0.91)。
- 在≥1%阈值下,每种克隆的评分者间一致性约为80%。
临床怎么用
- 作者认为两种检测可能可互换用于辅助筛选接受一线和二线帕博利珠单抗及潜在其他抗PD-1/PD-L1检查点抑制剂治疗的NSCLC患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Among the several agents targeting the programmed cell death 1 (PD-1) pathway, pembrolizumab is currently the only one approved for the treatment of patients with NSCLC in association with a companion diagnostic assay, the anti-PD-L1 immunohistochemical (IHC) 22C3 PharmDx (Agilent Technologies, Santa Clara, CA) using the Dako Autostainer (Dako, Carpinteria, CA). However, the Dako platform is not present in each pathology department, and this technical limitation is a major problem for the diffusion of the PD-L1 IHC predictive test for pembrolizumab. METHODS: The Italian Society of Anatomic Pathology and Cytopathology and the Italian Association of Medical Oncology in an independent, multicenter study compared the in vitro diagnostics PD-L1 IHC 22C3 pharmDx test (Agilent) on the Dako Autostainer and the in vitro diagnostics Ventana PD-L1 (SP263) test on the Ventana BenchMark platform (Ventana Medical Systems, Tucson, AZ). Using serial sections from tissue microarrays, 100 lung adenocarcinomas were locally stained and scored in four centers with the same antibody batches. RESULTS: A high analytical correlation (more than 90% at the lower 95% confidence interval [CI] value) between PD-L1 expression levels obtained with the 22C3 and SP263 assays was observed. At the proposed clinically relevant cutoffs (≥50% and ≥1%), the overall concordances between 22C3 and SP263 data were 0.99 (95% CI: 0.96-1) and 0.80 (95% CI: 0.68-0.91), respectively. The lower agreement between data obtained with the 22C3 and SP263 clones at the cutoff of 1% or higher was mainly related to the lower (about 80%) interrater agreement at this cutoff with each clone. CONCLUSIONS: These results indicate a high correlation between PD-L1 IHC expression data obtained with the Agilent PD-L1 IHC 22C3 pharmDx and the Ventana PD-L1 (SP263) tests in NSCLC and suggest that the two assays could be utilized interchangeably as an aid to select patients for first-line and second-line treatment with pembrolizumab and potentially with other anti-PD-1/PD-L1 checkpoint inhibitors.
引用
- Marchetti A, Barberis M, Franco R, et al. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors. J Thorac Oncol. 2017. PMID: 28818609. doi:10.1016/j.jtho.2017.07.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。